Saniona 過去の業績

過去基準チェック /06

Sanionaの収益は年間平均-9.7%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間7.7% 3.7%割合で増加しています。

主要情報

-9.7%

収益成長率

2.2%

EPS成長率

Biotechs 業界の成長	0.7%
収益成長率	3.7%
株主資本利益率	-1,179.8%
ネット・マージン	-328.8%
次回の業績アップデート	27 Feb 2025

Recent updates

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

Jan 06

Is Saniona (STO:SANION) Using Too Much Debt?

Dec 02

収支内訳

Saniona の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OM:SANION 収益、費用、利益 ( )SEK Millions
日付	収益	収益	G+A経費
30 Jun 24	25	-82	76
31 Mar 24	21	-83	77
31 Dec 23	17	-96	81
30 Sep 23	15	-108	52
30 Jun 23	12	-33	44
31 Mar 23	11	-100	113
31 Dec 22	15	-212	229
30 Sep 22	15	-334	330
30 Jun 22	15	-445	439
31 Mar 22	14	-461	450
31 Dec 21	10	-411	409
30 Sep 21	9	-326	352
30 Jun 21	9	-280	300
31 Mar 21	9	-200	225
31 Dec 20	8	-73	160
30 Sep 20	11	-25	113
30 Jun 20	9	-5	102
31 Mar 20	8	-1	95
31 Dec 19	7	-69	95
30 Sep 19	5	-96	110
30 Jun 19	49	-53	108
31 Mar 19	52	-52	115
31 Dec 18	55	-41	104
30 Sep 18	57	-32	89
30 Jun 18	17	-61	85
31 Mar 18	17	-56	79
31 Dec 17	21	-49	74
30 Sep 17	21	-47	74
30 Jun 17	68	-6	71
31 Mar 17	67	-2	67
31 Dec 16	75	2	69
30 Sep 16	71	10	56
30 Jun 16	23	-25	52
31 Mar 16	25	-21	46
31 Dec 15	14	-23	39
30 Sep 15	16	-23	41
30 Jun 15	19	-16	36
31 Mar 15	23	-10	33
31 Dec 14	22	-6	27
31 Dec 13	13	-1	14

質の高い収益: SANIONは現在利益が出ていません。

利益率の向上: SANIONは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: SANIONは利益が出ておらず、過去 5 年間で損失は年間9.7%の割合で増加しています。

成長の加速: SANIONの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SANIONは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: SANIONは現在利益が出ていないため、自己資本利益率 ( -1179.78% ) はマイナスです。

Saniona 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Saniona AB (publ) to Report Q2, 2025 Results on Aug 28, 2025

Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023)

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Recent updates

Saniona AB (publ) to Report Q2, 2025 Results on Aug 28, 2025

Is Saniona (STO:SANION) Using Debt Sensibly?

Saniona Initiates SAN711 Biomarker Study

Saniona Receives Regulatory Approval for San711 Biomarker Study

New major risk - Financial position

Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023)

Is Saniona (STO:SANION) Weighed On By Its Debt Load?

New minor risk - Share price stability

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

New major risk - Shareholder dilution

Price target decreased by 37% to kr6.00

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

Is Saniona (STO:SANION) Using Too Much Debt?

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

President & CEO recently bought kr100k worth of stock

Independent Chairman of the Board recently bought kr229k worth of stock

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Is Saniona (STO:SANION) Using Too Much Debt?

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: kr18.70

Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: kr20.10

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

New 90-day low: kr20.70

Saniona Announces Management Appointments

Co-Founder recently bought kr108k worth of stock

Co-Founder recently bought kr115k worth of stock

New 90-day low: kr22.55

Is Saniona (STO:SANION) Using Too Much Debt?

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: kr24.70

過去基準チェック /06